Close Menu

NEW YORK (GenomeWeb) – Natera plans to launch version three of its noninvasive prenatal test Panorama this year, which will include improved detection of the 22q microdeletion syndrome, the company said last week during a conference call discussing its second quarter 2016 performance.

The firm said that it is making progress in reimbursement for Panorama, but that reimbursement for microdeletion testing will decline in the near term.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.